Tirzepatide, a once-weekly injection to treat diabetes and obesity, is no longer in shortage, the FDA announced, potentially signaling a crackdown on copycat drugs in early 2025.MarsBars/Getty ImagesTirzepatide, the active ingredient in Zepbound and Mounjaro, is no longer in short supply, the FDA says.Cheaper versions of the drug, known as compounded tirzepatide, might be restricted in 2025.Patients could face higher costs and tougher access, and telehealth is racing to adapt.The FDA has announced that popular weight loss medication tirzepatide is no longer in shortage, potentially removing cheaper versions of the drug from the market by early 2025.Tirzepatide is the active ingredient in Eli Lilly's drugs Mounjaro and Zepbound, branded to treat diabetes and obesity, respectively.They're part of a class of medications called GLP-1 agonists, including semaglutide (sold as Ozempic and Wegovy), which have transformed obesity treatment in recent years.
The Shortage Of Popular Weight Loss Drug Tirzepatide Is Over, Fda Says. Patients Could See Higher Costs As A Result.
glandsverk@insider.com (Gabby Landsverk), Business Insider
Tue, 12/24/2024 - 2:08pm
Topics: imagestirzepatide mounjaro wegovy 059.with ted kyle fda-approved scott brunner ceo alliance pharmacy compounding linkedin january 2025.as henry meds hims lilly type i zepbound ro fda eli lilly ozempic it business insider december glp-1 glp-1s shortage compounded drugs announced offer telehealth early longer access brand-name cheaper treat years treatment body meet demand case sold
BING NEWS:
- FDA Approves Weight Loss Medication Zepbound to Treat Sleep Apnea
The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as tirzepatide, to help people treat their obstructive sleep apnea.
12/24/2024 - 11:05 am | View Link - Off-brand versions of Lilly weight loss drug must be pulled off market, could mean higher prices
The United States Food and Drug Administration ... concerns. "FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 drugs, including semaglutide and ...
12/24/2024 - 10:31 am | View Link - The FDA says the shortage of popular weight loss drug Zepbound is over. Here's what that means for patients.
Tirzepatide, the active ingredient in Zepbound and Mounjaro, is no longer in short supply, the FDA says.Cheaper versions of the drug, known as compounded tirzepatide, might be restricted in ...
12/24/2024 - 8:08 am | View Link - FDA says shortage of GLP-1 tirzepatide is over
The US Food and Drug Administration re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss medication tirzepatide is over.
12/23/2024 - 7:24 pm | View Link - FDA approves generic in same class as Ozempic for diabetes. Could it ease shortage, price?
In a move that could eventually make weight loss drugs cheaper and easier to access, the Food and Drug Administration ... since the FDA approved Ozempic for diabetes in 2017. Last week, the FDA said ...
12/23/2024 - 10:06 am | View Link - More
Welcome to Wopular
Wopular is an
online newspaper rack,
giving you a summary view of the top headlines from the top news sites.
Senh Duong (Founder)
Wopular,
MWB,
RottenTomatoes
MoviesWithButter : Our Sister Site
- "Expendables 4" Starts Shooting This Fall, Says Randy Couture at the Arnold Sports Festival more
- “Expendables 4” Gets Funding Interest from “Ip Man 3” Financier more
- "Ip Man 3" Distributor Suspected of Box Office Fraud, Parent Company Loses $200M in Market Cap more
- Yen Targets "Ip Man 4" for 2018 Release; Discusses Film with Director, Producer more
- "Ip Man 3" Shatters Expectations with $72M Opening [China Box Office] more